« Return to News | Clinical Intelligence

ImmunoGen touts new drug-delivering antibodies

Tuesday, March 8, 2011 10:33 AM

After forming partnerships with several major pharmaceutical companies, Waltham, Mass.-based biotech ImmunoGen wants to boost its pipeline of antibody-drug conjugates.

ImmunoGen is known for providing the technology for Roche/Genentech's experimental T-DM1, enabling a cancer-killing toxin to be linked to the approved antibody drug Herceptin to treat certain patients with breast cancer. While that is the latest-stage candidate to use ImmunoGen's technology, the firm has its own compounds that could bolster its future prospects.

One of the compounds in an early-stage clinical trial, called IMGN529, is an antibody that targets non-Hodgkin's lymphomas and that includes a special toxin. The toxin is supposed to remain linked to the antibody in a patient's bloodstream, until the compound reaches the targeted cancer site. This approach targets specific tumors with the antibody while delivering a potent toxin against the cancer. ImmunoGen aims to file with the FDA by mid-2011 for approval to begin early human trials with the new compound.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.